Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.190
+0.240 (8.14%)
At close: Dec 20, 2024, 4:00 PM
3.400
+0.210 (6.58%)
After-hours: Dec 20, 2024, 6:17 PM EST
Company Description
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases.
It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dr. Regina Graul Ph.D. |
Contact Details
Address: 245 First Street, Riverview II, 18th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 857 327 8778 |
| Website | cyclerion.com |
Stock Details
| Ticker Symbol | CYCN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001755237 |
| CUSIP Number | 23255M105 |
| ISIN Number | US23255M2044 |
| Employer ID | 83-1895370 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Regina Graul Ph.D. | President |
| Rhonda M. Chicko C.P.A. | Chief Financial Officer |
| Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation |
| Jessica Rennekamp | Associate Director of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Jul 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 14, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |